Coronavirus: study confirms increased risk of thrombosis with AstraZeneca vaccine

Cases of thrombosis are more frequent after receiving the vaccine against coronavirus of AstraZeneca than after the Pfizer/BioNTech one, although cases are very rare, according to a study released Thursday.

“After a first dose (of vaccine AstraZeneca) it is noted 30% increased risk of thrombocytopenia compared to a first dose (of the Pfizer/BioNTech vaccine),” notes the large-scale study published by the British Medical Journal (BMJ).

LOOK: How COVID-19 can cause premature deaths years later

The thrombocytopenia is a form of thrombosis, that is, the formation of a blood clot with life-threatening consequences.

After the launch of vaccination campaigns against covid-19 since 2021, a link between vial vector vaccines was quickly suspected —AstraZeneca and Johnson & Johnson– and the occurrence of these blood disorders.

The study, carried out using health data from millions of patients in several countries in Europe and the United States, confirms that these thromboses are more frequent after the vaccination of AstraZenecaalthough they are very rare: 862 cases for more than one million vaccinated.

The risk appears to increase after the first dose. After the second there is no difference between the vaccines of AstraZeneca and Pfizer/BioNTech.

As for the Johnson & Johnson vaccine, the data points to an increased risk, but not clearly enough for the researchers to draw a conclusion.

The study comes above all to confirm “that all vaccines (anticovid) are safe and effective,” microbiologist Sarah Pitt told AFP, highlighting the “extremely rare” frequency of cases of thrombocytopenia.

Source: Elcomercio

Ronald Payne

I, Ronald Payne, am a journalist and author who dedicated his life to telling the stories that need to be said. I have over 7 years of experience as a reporter and editor, covering everything from politics to business to crime.